<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066698</url>
  </required_header>
  <id_info>
    <org_study_id>ST266-PED-202</org_study_id>
    <nct_id>NCT05066698</nct_id>
  </id_info>
  <brief_title>ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects</brief_title>
  <official_title>A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noveome Biotherapeutics, formerly Stemnion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IQVIA Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Noveome Biotherapeutics, formerly Stemnion</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the efficacy of ST266 eye drops in healing persistent&#xD;
      epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers&#xD;
      will enter into an additional 8-week open-label ST266 treatment period. All patients will be&#xD;
      followed for 3-months post-treatment for monitoring of safety and maintenance of&#xD;
      re-epithelialization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 13, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled trial with Open-Label Extension</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of subjects with clinical success between ST266 and placebo arms, defined as complete re-epithelialization of the corneal epithelial defect at any weekly visit during the first 8 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of ST266</measure>
    <time_frame>7 months</time_frame>
    <description>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) in subjects treated with ST266 versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to re-epithelialization</measure>
    <time_frame>8 weeks</time_frame>
    <description>Time (in days) to first complete re-epithelization of PED in subjects treated with ST266 versus placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of re-epithelialization</measure>
    <time_frame>12 weeks</time_frame>
    <description>Maintenance of corneal re-epithelization up to 12 weeks after the end of treatment in subjects treated with ST266 versus placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BCVA from Baseline</measure>
    <time_frame>7 months</time_frame>
    <description>Mean change in Best Corrected Visual Acuity (BCVA) from Baseline over time and maintenance up to 12 weeks after the end of treatment in subjects treated with ST266 versus placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Rescue Therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Incidence of need for rescue within 8 weeks in subjects treated with ST266 versus placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success in Open-Label Extension</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of subjects with complete re-epithelization of the corneal epithelial defect in the second 8 weeks of open label treatment based on the Independent Reading Center (IRC) image assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Lubricating Drops</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean usage of preservative-free lubricating drops used for comfort in subjects treated with ST266 versus placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean change in Visual Analog Scale (VAS) score from Baseline over time in subjects treated with ST266 versus placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Defect</measure>
    <time_frame>7 months</time_frame>
    <description>Size of epithelial defect</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Persistent Corneal Epithelial Defect</condition>
  <arm_group>
    <arm_group_label>ST266</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical ocular application: one drop in the study eye four times a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical ocular application: one drop in the study eye four times a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ST266</intervention_name>
    <description>Topical ocular application: one drop four times a day for eight weeks</description>
    <arm_group_label>ST266</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.67% Sodium Chloride Ophthalmic Solution</intervention_name>
    <description>Topical ocular application: one drop four times a day for eight weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Open-label ST266</intervention_name>
    <description>Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>ST266</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and non-pregnant/non-breastfeeding female subjects aged 18 years and older.&#xD;
&#xD;
          2. Subjects with a PED present for at least seven (7) days at the time of Screening.&#xD;
&#xD;
          3. The defect must be at least 1.0 mm (longest linear measurement) at Screening and&#xD;
             Baseline (Day 1) and must be measurable by slit lamp.&#xD;
&#xD;
          4. In the Investigator's opinion, the defect is persistent i.e., the defect has not shown&#xD;
             improvement despite conventional treatment such as tear supplements and bandage&#xD;
             contact lenses.&#xD;
&#xD;
          5. The original defect to the cornea must be the result of an injury, infection, disease,&#xD;
             or surgery to the eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects currently being treated with cenegermin or other rhNGF in the study eye.&#xD;
&#xD;
          2. Subjects currently using topical antibiotic eye drops in the study eye. Subjects on&#xD;
             current antibiotic therapy must be willing to switch to study-provided moxifloxacin.&#xD;
&#xD;
          3. Subjects currently taking topical steroids or corticosteroid-containing eye drops or&#xD;
             ointment in the study eye. Subjects currently taking systemic corticosteroids with a&#xD;
             dose of &gt;10mg/day prednisone or equivalent.&#xD;
&#xD;
          4. Subjects currently using topical antihistamine eye drops or vasoconstrictors in the&#xD;
             study eye.&#xD;
&#xD;
          5. Subjects currently using topical or local immunosuppressive agents (e.g., optic&#xD;
             cyclosporine or liftegrast) in the study eye.&#xD;
&#xD;
          6. Subjects who require treatment with autologous serum eyedrops or amnion products in&#xD;
             the study eye.&#xD;
&#xD;
          7. Subjects who need to use contact lenses for refractive correction during the study.&#xD;
&#xD;
          8. Subjects who require treatment with bandage contact lens or punctal plugs in the study&#xD;
             eye that cannot be removed.&#xD;
&#xD;
          9. Subjects currently taking antiviral medications for an active infection in the study&#xD;
             eye. Subjects taking antiviral medications for prophylaxis may be enrolled in the&#xD;
             study at the Investigator's discretion, provided that the subject remain on a stable&#xD;
             dosing regimen throughout the duration of the study.&#xD;
&#xD;
         10. History of ocular surgery (including laser or refractive surgery) in the study eye&#xD;
             within 3 months prior to study screening.&#xD;
&#xD;
         11. Subjects with an uncontrolled lid or ocular infection in the study eye.&#xD;
&#xD;
         12. History of alkali burns of the cornea.&#xD;
&#xD;
         13. The circumference affected by limbal blood vessel ischemia is greater than 75 percent&#xD;
             of the limbal circulation.&#xD;
&#xD;
         14. Subjects with severe lid abnormalities contributory to the persistence of the PED such&#xD;
             as inability to close the lids.&#xD;
&#xD;
         15. Subjects who have a history of AIDS or HIV.&#xD;
&#xD;
         16. Subjects who have participated in a clinical trial (including a previous study&#xD;
             involving ST266) within 30 days prior to Day 1.&#xD;
&#xD;
         17. Subjects who have more than one distinct PED in the study eye prior to screening&#xD;
             visits. Subjects who develop PEDs after the screening visit will remain in the study;&#xD;
             however, only the original study PED will be assessed.&#xD;
&#xD;
         18. For subjects with bilateral PEDs, only the eye with the larger PED should be entered&#xD;
             into the study. The non-study eye will receive standard of care treatment and be&#xD;
             observed throughout the trial.&#xD;
&#xD;
         19. Subjects with bullous keratopathy in the study eye.&#xD;
&#xD;
         20. Subjects with corneal perforation or impending corneal perforation in the study eye.&#xD;
&#xD;
         21. Subjects with uncontrolled glaucoma.&#xD;
&#xD;
         22. Female subjects who are pregnant or breastfeeding. Female subjects who are neither&#xD;
             postmenopausal for at least 1 year nor surgically sterile require a negative urine&#xD;
             pregnancy test. All subjects must use an acceptable form of birth control during the&#xD;
             study such as abstinence, barrier method, or hormonal contraceptive.&#xD;
&#xD;
         23. Epithelial defect was classified as a progressive corneal melt caused by an&#xD;
             immunological process such as rheumatoid melt or Mooren's ulceration.&#xD;
&#xD;
         24. Subjects with recurrent corneal erosion or corneal basement membrane dystrophy.&#xD;
&#xD;
         25. Known hypersensitivity to study provided lubricating drops, antibiotic drops, and/or&#xD;
             procedural medications such as fluorescein dye.&#xD;
&#xD;
         26. Consideration by the Investigator, for any reason, that the subject is an unsuitable&#xD;
             candidate to receive ST266.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Urling</last_name>
    <phone>412-402-9976</phone>
    <email>aurling@noveome.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Trinity Research Group</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastian Heersink, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alireza Ghaffarieh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantis Eye Care</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dwayne Logan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie Deng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christopher Ta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Doheny Eye Center</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hugo Hsu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Eye Specialists Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jay Patel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bowden Eye &amp; Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32259</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Frank Bowden, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shettle Eye Research</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33733</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Phillip Lee Shettle, DO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Millennium Clinical Research, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Salomon Esquenazi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedEye Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Zachary Segal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marietta Eye Clinic</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Puneet Panda, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Edward Holland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Eye Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bennie Jeng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Pedram Hamrah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joseph Ciolino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital &amp; Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarkis Soukiasian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Eye Specialists- Ophthalmology</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shachar Tauber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNMC Truhlsen Eye Institute</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brent Timperley, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNC Kittner Eye Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hussam Banna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Nordlund, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSU Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrew Hendershot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Partners, PC</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brandon Ayres, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine Shieh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush Eye Associates</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sloan Rush, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>John Goosey, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Masih Ahmed, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blanton Eye Institute/Houston Methodist Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rahul Pandit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Eye Research Center</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jerry Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>R and R Eye Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Charles Reilly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piedmont Eye Center</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>34502</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>James Paauw, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>WVU Eye Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lingo Lai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eye Centers of Racine and Kenosha</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Radha Sanka, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Nehls, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

